W

bioLLM/wiki

LLM-Synthesized Biotech Database

Live

STAT3

STAT3

Overview

Signal Transducer and Activator of Transcription 3 (STAT3) is a multifunctional transcription factor that serves as a central node in numerous cytokine and growth factor signaling cascades. Upon activation — most characteristically via phosphorylation at Tyrosine 705 (Tyr705) by upstream kinases such as JAKs — STAT3 dimerizes, translocates to the nucleus, and drives transcription of genes governing cell survival, proliferation, differentiation, and immune modulation. Physiologically, STAT3 is activated downstream of cytokines such as interleukin-6 and growth factors including IGF1, making it a critical regulator of tissue homeostasis and inflammation. Its activity is tightly coupled to co-regulatory networks involving pathways such as PI3K/AKT and HIF-1α, underscoring its role as an integrative signal hub.

In disease contexts, STAT3 is one of the most extensively studied oncogenic transcription factors. Aberrant or sustained STAT3 activation has been documented across a broad range of malignancies — including breast cancer, bladder cancer, and hepatic metastatic disease — where it shapes both tumor cell behavior and the surrounding tumor microenvironment. Beyond oncology, STAT3 has emerged as a regulator in fibrotic diseases and in the biology of aging skeletal muscle, reflecting its broad pathophysiological relevance and its attractiveness as a therapeutic target.

Focus of Latest Publications

Recent publications continue to position STAT3 as a central signaling node in cancer, fibrosis, and immune regulation. In a network pharmacology and molecular docking study of the polyherbal nutraceutical Vernolac, STAT3 emerged among the key hub targets alongside Akt1, B-cell lymphoma 2, EGFR, ESR1, HSP90AA1, IL6, SRC, and TNF. The analysis linked Vernolac’s phytochemicals, including thymoquinone, quercetin, carvacrol, and vernolactone, to multiple cancer-related pathways, suggesting that STAT3-associated signaling may contribute to the formulation’s proposed anticancer activity. The same study also reported selective antiproliferative effects in cancer cell lines, supporting further preclinical evaluation of this multi-target approach.

STAT3 was also highlighted in studies of fibrotic disease. In systemic sclerosis, combined all-trans retinoic acid and rosiglitazone were reported to alleviate fibrosis by suppressing the STAT3/Th17 axis, indicating a mechanistic link between STAT3 signaling and profibrotic immune responses. In pulmonary fibrosis, diammonium glycyrrhizinate and vitamin D3 were described as synergistically inhibiting epithelial-mesenchymal transition through modulation of crosstalk between STAT3/HSP90AA1 and the HIF-1α pathway. Together, these studies reinforce STAT3 as a therapeutic target in fibrotic remodeling and inflammatory signaling.

In cancer immunology, STAT3 was implicated in the immunosuppressive effects of Cdk4/6 inhibition in HR+/HER2- breast cancer. palbociclib was shown to promote fibroblast senescence and increase IGF1 and FGF7, which in turn drove macrophage polarization toward an M2-like phenotype through STAT3 Tyr705 phosphorylation and ARG1 upregulation, leading to arginine depletion and reduced lymphocyte viability. The CSF1R inhibitor pexidartinib countered this effect by suppressing STAT3 phosphorylation and ARG1 expression, improving lymphocyte viability and enhancing palbociclib’s antitumor activity. A separate review on B7-H3/CD276 also identified STAT3 as one of the pathways activated by this checkpoint protein in exosome biology and the tumor microenvironment, linking STAT3 to vesicle-mediated oncogenic signaling and immune evasion.

Beyond disease-specific studies, STAT3 continues to appear as a recurrent target in drug discovery and systems biology analyses. A review of integrated molecular docking and machine learning approaches noted that these methods have enabled discovery of nanomolar inhibitors against STAT3 and other targets. In skeletal muscle aging research, STAT3 was identified as one of four transcription factors associated with overlapping transcriptomic changes induced by caloric restriction and endurance exercise, suggesting a possible role in longevity-related regulatory networks. Collectively, these recent publications portray STAT3 as a versatile signaling hub connected to cancer progression, fibrosis, immune suppression, and aging-related biology.

Key Publications

  • NEWJul A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer. (PloS one, 2026, PMID 42384725): "Protein-protein interaction analysis using STRING and Cytoscape revealed fourteen key hub nodes, including AKT1, BCL2, CASP3, CTNNB1, EGFR, ESR1, GAPDH, HSP90AA1, HSP90AB1, IL6, JUN, SRC, STAT3, and TNF."
  • NEWJan Combined All-trans Retinoic Acid and Rosiglitazone Alleviates Scleroderma Fibrosis by Suppressing the STAT3/Th17 Axis. (In vivo (Athens, Greece), 2026, PMID 42379744): "Combined All-trans Retinoic Acid and Rosiglitazone Alleviates Scleroderma Fibrosis by Suppressing the STAT3/Th17 Axis."
  • Apr CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2- breast cancer. (Oncogene, 2026, PMID 41986650): "These factors drive macrophage polarization toward an M2-like phenotype through STAT3 Tyr705 phosphorylation and ARG1 upregulation, resulting in arginine depletion and reduced lymphocyte viability."
  • Apr B7-H3 (CD276) in exosome biogenesis and the tumor microenvironment: a new therapeutic nexus. (Cell communication and signaling : CCS, 2026, PMID 41964005): "Mechanistically, B7-H3 activates pathways such as STAT3, PI3K, and lipid metabolism, thereby amplifying oncogenic signaling and promoting a pro-tumor TME."
  • Apr Innovative integration of molecular docking and machine learning for drug discovery: from virtual screening to nanomolar inhibitors. (Chemical communications (Cambridge, England), 2026, PMID 41841313): "These approaches have enabled the discovery of nanomolar inhibitors against multiple therapeutic targets including STAT3, TTK, LSD-1, and HER2."
  • Apr Exploration of the co-regulatory mechanism of calorie restriction and endurance exercise on elderly skeletal muscle and its potential intervention targets. (Experimental gerontology, 2026, PMID 41794155): "Additionally, we identified 10 key genes (such as LPL, PPARGC1A, and IGF1), 4 transcription factors (FOXC1, POU2F2, GATA2, and STAT3), and 4 microRNAs (miR-155-5p, miR-124-3p, miR-1-3p, and miR-16-5p) interacting with these genes."
  • Apr Synergistic effects of diammonium glycyrrhizinate and vitamin D3 against EMT in pulmonary fibrosis through modulating the crosstalk of STAT3/HSP90AA1 and HIF-1α pathway. (Journal of ethnopharmacology, 2026, PMID 41423159): "...modulating the crosstalk of STAT3/HSP90AA1 and HIF-1α pathway."
Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.